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We report here the development of radioiodinated styrylchromone derivatives with 
alkoxy groups as single photon emission computed tomography (SPECT) imaging probes for 
cerebral amyloid-β (Aβ) plaques. Among the derivatives, the methoxy derivative 14 and the 
dimethoxy derivative 15 displayed relatively high affinity for the Aβ(1–42) aggregates with 
Ki values of 22 and 46 nM, respectively. Fluorescent imaging demonstrated that 14 and 15 
clearly labeled thioflavin-S positive Aβ plaques in the brain sections of Tg2576 transgenic 
mice. In the in vivo studies, [125I]14 and [125I]15 showed high initial brain uptake expressed as 
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the percentage of the injected dose per gram (2.25% and 2.49% ID/g at 2 min, respectively) 
with favorable clearance (0.12% and 0.20% ID/g at 180 min, respectively) from the brain 
tissue of normal mice. Furthermore, in vitro autoradiography confirmed that [125I]15 binds 
thioflavin-S positive regions in Tg2576 mouse brain sections. The derivative 15 may be a 
potential scaffold for the development of in vivo imaging probes targeting Aβ plaques in the 
brain. In particular, further structural modifications are required to improve the compounds 
binding affinity for Aβ.  
 
Key words: Alzheimer’s disease, amyloid-β plaque, styrylchromone, single photon emission 
computed tomography (SPECT). 
 
Alzheimer’s disease (AD), which is the most common cause of dementia in the elderly, 
is characterized by the progressive decline of cognition including learning and memory1. It is 
estimated that the number of patients with AD will increase to over 100 million by the year 
2050 and, for this reason, effective therapies need to be developed to prevent the collapse 
ofglobal health-care systems2. Aβ plaques have been detected in patients prior to the 
appearance of the clinical symptoms of AD. This implies that the detection and early initiation 
of treatment targeting Aβ deposits could be an effective therapeutic option to improve the 
symptoms of AD patients in the early disease stage2,3. Nuclear medicine imaging techniques 
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have been accepted as useful tools for the early detection of cerebral Aβ plaque deposits4.  
Numerous studies have reported the development of positron emission tomography (PET) and 
SPECT imaging probes of Aβ plaques in the living brain5-7. In particular, 18F-flutemetamol, 
18F-florbetapir and 18F-florbetaben have demonstrated highly correlated brain distribution 
patterns with post-mortem existence of Aβ plaques. Recently, these PET tracers were 
approved by the US Food and Drug Administration (FDA) for the specific detection of Aβ 
plaques inclinical practice8-10. In contrast, there are currently no effective SPECT probes for 
detecting Aβ plaques despite their convenience and widespread utilization. SPECT is widely 
available in most hospitals, and is generally less expensive, as compared to PET11,12. 
Accordingly, the development of clinically useful SPECT imaging probes for Aβ can facilitate 
and encourage the initial diagnosis of AD in elderly people. Previously, we have developed 
flavonoid derivatives such as flavones, chalcones, aurones, and styrylchromones as 
prospective Aβ imaging probes, although clinically available compounds have not yet been 
developed13-22. We found that radioiodinated styrylchromones (SCs) with amino groups (NH2, 
NHMe, and NMe2) bind to Aβ aggregates with high binding affinities. However, their initial 
uptake and washout from normal mice brain tissue were inadequate for in vivo imaging22. 
Therefore, we hypothesized that the structural modification of SCs may improve the in vivo 
brain distribution and thereby, provide useful Aβ imaging agents. Previously, we reported that 
radioiodinated flavonoids such as flavone, chalcone, and aurone derivatives with alkoxy 
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groups at the p-position of the phenyl ring showed good initial brain uptake and washout from 
the normal brain without crucial decline in binding affinity for Aβ13,19,21. Therefore, we 
considered that the introduction of alkoxy groups to the structure of SCs could improve their 
in vivo brain distribution. For this reason, we designed new radioiodinated SCs derivatives, 
which have alkoxy groups introduced into the 2-phenyl ring of the original structure. We 
envisaged that this structural modification would enable their application in SPECT diagnosis. 
The synthesis of the alkoxy SC derivatives is presented in Scheme 1. O-acylation of the 
5’-bromo-2’-hydroxyacetophenone with the appropriate cinnamoyl chlorides provided phenyl 
cinnamates 1-3. The Baker–Venkataraman rearrangement of the phenyl cinnamates using 
KOH gave the corresponding 1,3-diketones 4-6. The treatment of these 1,3-diketones with a 
mixture of H2SO4 and AcOH led to their cyclodehydration yielding (E)-2-styrylchromones 
7-9. These styrylchromones were converted to tributyltin derivatives 10-12 using a 
bromo-to-tributyltin exchange reaction catalyzed by Pd(0). The resulting tributyltin 
derivatives were reacted with iodine in CHCl3 to form the target iodo derivatives 13-15. 
Methoxy derivative 14 was converted to phenol derivative 16 by demethylation with BBr3 in 
CH2Cl2. Alkylation of 16 with ethylene chlorohydrin, ethylene glycol mono-2-chloroethyl 
ether, or 2-[2-(2-chloroethoxy)ethoxy]ethanolusing potassium carbonate resulted in 
oligoethyleneoxy derivatives 17, 18, and 19, respectively. 
In vitro binding experiments to evaluate, the binding affinity of the SC derivatives for 
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Aβ were performed. We used suspensions of Aβ(1–42) aggregates with 125I-labeled 
4-dimethylamino-4’-iodo-styrylchromone (20), which showed high binding affinity for Aβ 
aggregates (Kd= 8.7 nM) in our previous studies22. The inhibition constant (Ki) values of the 
SCs for the Aβ aggregates ranged from 21.9 to 553nM (Table 1). Derivative 13, which 
contained an unsubstituted 2-phenyl ring, displayed weak affinity for Aβ aggregates (Ki = 198 
nM). In contrast, methoxy derivative 14 (Ki = 21 nM) showed a 9-fold improvement in 
binding affinity versus 13, displaying comparable affinity to dimethylamino derivative 20 (Ki 
= 22 nM). Accordingly, the presence of a methoxy group at R1 may have a crucial role in 
binding interactions with Aβ aggregates. Dimethoxy derivative 15 had a reasonable binding 
affinity (Ki = 46 nM), suggesting that the introduction of a methoxy group at the R2 position 
can retain binding affinity. However, introduction of a hydroxyl group at the R1 position did 
not improve the binding affinity. Indeed, hydroxyl derivative 16 displayed a negligible Aβ 
binding affinity (Ki = 121 nM). The oligoethyleneoxy derivatives 17-19 exhibited reduced 
binding affinities (Ki = 415-553 nM), which were over 20-fold lower than 14. In our previous 
study, the introduction of oligoethyleneoxy groups to the phenyl ring of radioiodinated 
aurones did not considerably alter Aβ aggregate binding21. In this study, we observed the 
opposite effect, in that the presence of oligoethyleneoxy groups on the 2-phenyl ring of the 
SCs clearly had a deleterious effect on Aβ aggregate binding affinity. These facts suggest that 
SCs and aurones may exhibit different binding interactions with Aβ aggregates, although the 
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mechanisms remain largely unclear. 
Based on the in vitro results, we selected 14 and 15 for further biological evaluation. 
Fluorescence imaging experiments with the SCs were performed using brain slices from a 
transgenic mouse (Tg2576) model of Aβ deposition. A number of fluorescence spots denoting 
derivatives 14 and 15 were observed in the mouse brain slices (Figs. 2A and B). The labeling 
patterns of these compounds corresponded to the fluorescence signals obtained with 
thioflavin-S staining (Figs. 2C and D). In contrast, there was no significant fluorescence for 
14 and 15 in the brain slices from wild-type mice (Figs. 2E and F). There was no marked 
autofluorescence detected in any brain slices (data not shown). These results indicate that 14 
and 15 have specific binding potential to Aβ plaques in the mouse brain. 
For the biodistribution study and in vitro autoradiography, 125I-labeled SC derivatives 
([125I]14, [125I]15) were synthesized by an iododestannylation reaction of tributyltin 
derivatives (11 and 12) with hydrogen peroxide as an oxidant (Scheme 2). Using HPLC 
systems, the radioligands were purified, and the radiochemical qualities of these ligands were 
analyzed by co-injection of non-radioactive compounds. The radioiodinated products were 
obtained in radiochemical yields of 40-75% with a radiochemical purity of >95%. Clinically 
available SPECT imaging probes for the Aβ plaque should show a high initial brain uptake 
and rapid clearance from non-target regions in the brain. Therefore, biodistribution studies of 
[125I]14 and [125I]15 were conducted in normal mice and expressed as % of injected dose per 
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gram (%ID/g) (Table 2). The compounds [125I]14 and [125I]15 exhibited a high initial brain 
uptake (2.3% and 2.5% ID/g at 2 min, respectively) and a favorable brain clearance (0.1% 
and 0.2% ID/g at 180 min, respectively). The brain2min/brain60min ratio of 18F has been used as 
an index of brain washout23,24. The brain2min/brain60min ratio of clinically used [18F]Florbetapir 
([18F]AV-45) and [18F]Florbetaben ([18F]BAY94-917218) was reported to be 3.823 and 4.825, 
respectively. Since the brain2min/brain60min ratio of [125I]14 and [125I]15 was calculated to be 
4.5 and 3.3, respectively, the washout index of these [125I]SC derivatives seems to be 
comparable to the aforementioned PET probes. Additionally, because the half-life of 
radioactive iodine 123I, used for SPECT, is much longer than that of 18F (13.2 h vs 110 min), 
the brain2min/brain180min ratio can be used as another index of brain washout in this study. The 
brain2min/brain180min ratios of [125I]14 and [125I]15 were 18.8 and 12.5, respectively, indicating 
that these two 125I-labeled SC derivatives have promising in vivo pharmacokinetics. 
Furthermore, the collective in vivo results suggested that the washout of [125I]14 from the 
normal brain tissue was faster than that of [125I]15. Both [125I]14 and [125I]15 demonstrated 
increased radioactivity in the stomach over time, and peaked at 5.0% and 5.2% ID/g at 60 
min, respectively, suggesting that these SCs were gradually deionidated in vivo. Since brain 
uptake of these tracers rapidly declined with time, it is unlikely that the metabolites could 
easily penetrate the blood brain barrier. Consistent with our previous study22, relatively low 
initial brain uptake and high brain retention of the dimethylamino derivative [125I]20 (1.20% 
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ID/g at 2 min and 0.38% ID/g at 180 min) was observed, compared with the methoxy 
derivatives. It is reported that radiotracers with a low molecular weight (<500 Da) and a 
moderate lipophilicity (logD7.4 values, 2.0–3.5) show optimal passive brain entry in vivo26,27.  
Although the molecular weights of the 125I-labeled compounds in this study are all within the 
specified range (Table 2), the most lipophilic [125I]20 showed a relatively low blood-brain 
barrier permeability. Taken together, these results indicate that the substitution of a 
dimethylamino group with methoxy groups at the 2-phenyl ring position of the SCs structure 
improves its brain distribution for in vivo imaging.  
To further characterize [125I]14 and [125I]15 as possible imaging probes for specifically 
targeting Aβ plaques, in vitro autoradiography was performed using brain sections from the 
Tg2576 mice. Although some [125I]14 spots in the brain slices corresponded to thioflavin-S 
stained regions, the overall [125I]14 image was inconsistent with the existence of Aβ plaques 
(Fig. 3A and 3C). In contrast, clear [125I]15 autoradiographic images were observed in the 
thioflavin-S positive regions (Fig. 3B and 3D). The discrepancy between the fluorescence and 
autoradiographic images of these SC derivatives could have been caused by the different 
concentration of the compounds. The concentration of the SCs was 100 μM for the 
fluorescence staining while only 0.3 nM of 125I labeled SCs was used in the autoradiography 
studies. It is unclear why only the [125I]15 displayed a clear autoradiograph for Aβ plaques, 
despite the fact that derivative 15 possesses a lower binding affinity for the Aβ aggregates 
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than 14 (Table 1). Several factors may have contributed to these results, including the 
selectivity for Aβ plaques over other brain components, degree of nonspecific binding, and 
conformation differences between the Aβ aggregates and Aβ plaques in the brain of Tg2576 
mice. Regardless, the [125I]15 may be a potential lead compound for the development of in 
vivo imaging probes for Aβ plaques in the brain. Further structural modification of the SC 
derivatives can provide promising Aβ imaging probes.  
In conclusion, we demonstrated that radioiodinated styrylchromone derivatives with 
methoxy groups had preferable pharmacokinetics for in vivo imaging without significant 
reduction in binding affinity for the Aβ aggregates. In particular, both fluorescent imaging and 
autoradiography showed that the dimethoxy derivative [125I]15 labeled the thioflavin-S 
positive Aβ plaques in sections of the Tg2576 mouse brain. Further structural modifications 
based on derivative 15 may facilitate the development of clinically useful Aβ imaging probes. 
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1: R1= H, R2= H
2: R1= OCH3, R2= H
3: R1= OCH3, R2= OCH3
4: R1= H, R2= H
5: R1= OCH3, R2= H
6: R1= OCH3, R2= OCH3
7: R1= H, R2= H
8: R1= OCH3, R2= H
9: R1= OCH3, R2= OCH3
10: R1= H, R2= H
11: R1= OCH3, R2= H
12: R1= OCH3, R2= OCH3
13: R1= H, R2= H
14: R1= OCH3, R2= H


























Reagents and conditions: (a) 1) SOCl2, DMF, reflux 1 h, 2) 5'-Bromo-2'- 
hydroxyacetophenone, pyridine, reflux, 3 h; (b) pyridine, KOH, reflux, 1h; (c) H2SO4, AcOH, 
reflux, 1 h then r.t., 1h; (d) (SnBu3)2, Pd(PPh3)4, Et3N, dioxane, reflux, 7 h, (e) I2, CHCl3, r.t., 




Fuchigami et al. Page 15/23 
 












[125I]14: R1= OCH3, R2= H
[125I]15: R1= OCH3, R2= OCH3
11: R1= OCH3, R2= H
12: R1= OCH3, R2= OCH3  
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13: R1= H, R2= H
14: R1= OMe, R2= H
15: R1= OMe, R2= OMe
16: R1= OH, R2= H
17: R1= OCH2CH2OH, R2= H
18: R1= (OCH2CH2)2OH, R2= H
19: R1= (OCH2CH2)3OH, R2= H




Kia (nM)  Mw log Pb 
13  198 ± 48.0  374.1 − 
14   21.9 ±   5.10  404.2 2.15 
15  45.5 ± 10.7  434.2 2.14 
16  121 ± 20.8  390.2 1.87 
17  446 ± 100  434.2 − 
18  415  64.5  478.3 − 
19  553  135  522.3 − 
20 
 
  21.8 ± 3.35  417.3 2.65c 
 
Fuchigami et al. Page 17/23 
 
a Inhibition constant of styrylchromone derivatives were determined using [125I]20 as the 
ligand in Aβ aggregates. Each value (mean ± SEM) was determined by 3-6 independent 
experiments. 
b The partition coefficient between n-octanol and sodium phosphate buffer at pH 7.4 was 
determined by a conventional flask shaking method (n = 3). 
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Table 2. Biodistribution of radioactivity after i.v. injection of 125I labeled styrylchromone 
derivatives in normal mice. 
 
Time after injection (min) 
Organ 2 30 60 120 180 
 
[125I]14 
Blood 2.22 (0.31) 0.76 (0.09) 0.56 (0.13) 0.36 (0.08) 0.29 (0.04) 
Liver 20.90 (3.32) 14.72 (3.73) 9.10 (2.58) 6.53 (3.63) 3.38 (0.59) 
Kidney 10.06 (1.94) 4.50 (1.55) 2.20 (0.41) 1.28 (0.40) 0.85 (0.12) 
Intestine 1.70 (0.67) 10.41 (3.60) 18.57 (7.07) 22.64 (6.14) 18.82 (3.81) 
Spleen 3.81 (1.11) 1.19 (0.20) 0.82 (0.17) 0.70 (0.26) 0.55 (0.32) 
Lung  6.12 (1.61) 1.77 (0.33) 1.17 (0.28) 0.78 (0.18) 0.60 (0.19) 
Stomach 0.96 (0.26) 1.22 (0.88) 2.58 (2.09) 5.03 (4.15) 4.19 (1.37) 
Pancreas 5.26 (0.84) 1.44 (0.22) 1.06 (0.44) 0.82 (0.74) 0.68 (0.72) 
Heart 5.50 (1.08) 1.09 (0.08) 0.67 (0.15) 0.37 (0.10) 0.26 (0.08) 




Blood 3.42 (0.32) 1.25 (0.16) 0.74 (0.10) 0.61 (0.14) 0.33 (0.05) 
Liver 15.07 (1.39) 7.42 (1.46) 4.98 (1.39) 3.50 (0.82) 4.26 (0.80) 
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Kidney 12.28 (1.43) 4.74 (0.70) 2.37 (0.33) 1.51 (0.18) 1.09 (0.20) 
Intestine 1.71 (0.47) 12.19 (4.91) 15.93 (8.64) 27.37 (4.85) 23.16 (3.95) 
Spleen 4.86 (0.69) 1.62 (0.31) 1.04 (0.16) 0.80 (0.49) 1.33 (1.19) 
Lung  7.00 (0.99) 2.31 (0.31) 1.46 (0.18) 0.95 (0.11) 1.68 (2.48) 
Stomach 1.39 (0.18) 2.75 (2.17) 1.77 (0.53) 5.15 (3.29) 3.67 (2.82) 
Pancreas 7.17 (1.62) 2.95 (0.90) 1.13 (0.17) 0.76 (0.34) 0.42 (0.20) 
Heart 6.96 (0.93) 1.68 (0.23) 0.96 (0.13) 0.52 (0.08) 0.32 (0.08) 




Blood 2.24 (0.43) 1.20 (0.17) 1.02 (0.16) 1.07 (0.19) 1.09 (0.29) 
Liver 12.3 (2.65) 8.36 (2.01) 5.84 (1.18) 7.46 (2.61) 4.36 (1.29) 
Kidney 8.68 (2.05) 3.36 (1.25) 1.59 (0.66) 1.35 (0.55) 1.37 (0.41) 
Intestine 1.20 (0.48) 11.83 (2.26) 9.90 (5.68) 13.43 (5.52) 10.03 (2.58) 
Spleen 3.88 (1.94) 2.65 (0.45) 1.82 (0.45) 2.01 (0.89) 2.04 (0.29) 
Lung 8.83 (2.51) 3.85 (0.69) 2.54 (0.82) 2.27 (0.55) 1.96 (0.89) 
Stomach  1.01 (0.31) 1.88 (0.79) 1.79 (0.66) 3.15 (1.46) 3.38 (2.68) 
Pancreas 3.37 (0.59) 1.44 (0.58) 0.84 (0.14) 0.81 (0.31) 0.59 (0.21) 
Heart  5.51 (1.33) 1.26 (0.31) 0.66 (0.13) 0.63 (0.14) 0.64 (0.17) 
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Brain 1.20 (0.23) 1.13 (0.21) 0.62 (0.10) 0.44 (0.11) 0.38 (0.11) 
















































R= NMe2, NHMe, NH2, OMe, OH
Aurones Styrylchromones




Figure 2. Neuropathological staining of styrylchromone derivatives 14 (A) and 15 (B) in 10 
μm sections of Tg2576 mice brain. Labeled plaques were confirmed by staining of the 
adjacent sections with thioflavin-S (C and D). Fluorescence images of 14 (E) and 15 (F) in the 









Figure 3. In vitro autoradiograms of styrylchromone derivatives [125I]14 (A) and [125I]15 (B) 
in the brain sections of Tg2576 mouse brain. Fluorescence images of thioflavin-S in the 
adjacent section (C and D). 
